In recent years, concerns have been raised over ingredients in personal care products like skincare that may interfere with normal hormone function. This category of substances is broadly called endocrine disruptors as they can affect estrogen, testosterone, thyroid and other hormonal pathways in the body. Common endocrine disrupting chemicals that may be found in skincare formulations include parabens, phthalates, UV filters (benzophenones), soy extracts, and triclosan. And the list seems to grow as more research emerges.

But are ingredients in personal care products that affect hormones dangerous o beneficial?  It depends.  Incases of menopause when estrogen levels are low, it can be beneficial to have estrogen stimulating skincare ingredients.  However, in pregnancy and when trying to conceive and in breast cancer these may not be safe.

This blog will look at the ingredient in skincare products that affect your hormones and which are safe and which to avoid.

To get custom skincare advice, identify your Baumann Skin Type using our skin type quiz. 

We know that some ingredients in skincare can get into the skin and stimulate hormone receptors.  These are called agonist. So for example, an estrogen agonist is an ingredient that binds the estrogen receptor and gets it to have the same activity it would have if estrogen were to bind to it.  An “agonist” causes the same effect as the ingredient whose name precedes the word agonist.  so a testosterone agonist would act like testosterone.  An antagonist would block activity.  So an estrogen antagonist would block the effects of estrogen or estrogen agonists.

What we do not know- is how strong these effects are and if they cause any long term issues in the skin.  Frankly- long term studies just have not been done.  However, many skincare ingredients have been used for years and a causal relationships with them and health risks and disease has not been proven. So we really do not know if these are risky or not.  It seems prudent that if you are trying to conceive a baby, are in puberty, or have any hormone responsive tumors, it is a good idea to avoid these ingredients.

While cell culture and animal studies provide initial insight into potential endocrine disruption, extrapolating these findings to human risk levels has major limitations. High-dose toxicity testing poorly reflects much lower chronic exposures from daily skincare use. Further, biological differences can make animal results poorly predictive for humans. For example, rapidly metabolizing mice may not accumulate ingredients over decades like human skin and tissues. Or effects seen in mice given 10x their body weight in chemicals daily does not really translate a 0.1% concentration in a skincare serum applied occasionally by a person. So while preliminary lab tests suggest chemicals may influence pathways controlling vital hormones, real-world human exposures differ greatly in dose, frequency and duration. Significant knowledge gaps remain in understanding if skincare ingredients alter, for example, puberty timing, fertility or menopause in aging skin over years and decades. Too many variables differ between a cultured cell, a short-lived mouse, and a person using a complex mixture of products daily for skin health and appearance over a lifetime. So while we can identify chemicals with potential hormonal activity in the lab, defining real risk requires data better mimicking long-term, low-dose human exposures.

 Higher risk groups should exercise caution with exposures to hormones in skincare when possible. These sensitive high risk groups are people who are:

• pregnant 
• breastfeeding
• Infants 
• children still undergoing development
• in puberty
• planning to conceive (all genders)
• having fertility issues
• diagnosed with hormone-responsive cancers like breast, uterine and ovarian cancers
• undergoing gender reassignment

If you have any of these issues- it is prudent to avoid estrogen and estrogen agonists and other EDCs in skincare products.

An endocrine disruptor is a  chemical compound that interferes with or mimics natural hormones in the body's endocrine system. The endocrine system plays a vital role in regulating metabolism, reproduction, tissue function, growth and development through the release of hormones like estrogen, testosterone, thyroid hormone, and. Endocrine disrupting ingredients can bind to hormone receptors, blocking their action, increasing their action, or altering signaling pathways.

 Exposure to endocrine disruptors, even at low doses, may have concerning developmental, reproductive and other long-term health effects due to their influence on delicate hormonal pathways in the body over time. Further research is still needed on defining safe exposure thresholds for many suspected endocrine disruptors.

There are no reports of long term use of skincare products proven to cause hormonal changes.  There are no evidence-based trials to prove these endocrine disrupting  ingredients are risky.  However, if you are trying to conceive (men and women), are pregnant or breastfeeding, or have a hormone responsive cancer- it is a good idea to avoid any skincare products that may affect your natural hormones.

These endocrine disrupting ingredients may also build up in the water supply, marine life and other natural habitats and lead to long term issues, but environmental effects of these skincare ingredients will not be discussed in this blog.  Rather we will focus on the hormonal effects of ingredients in skincare on the human body.

Hormones like estrogen and testosterone are often prescribed in topical drug formulations to treat symptoms related to menopause, low testosterone and other conditions. Hormones penetrate really easily into the skin and often into the blood stream which is why many of these are used in patches or topical creams, gels and oils. 

Some ingredients commonly found in over-the-counter skincare products  interact with the body’s hormone receptors and endocrine pathways.  This means skincare ingredients applied topically on the skin have the potential to be absorbed and alter delicate hormonal balances and signaling in tissues the same way prescription hormonal drugs do. Unlike FDA approved medications, cosmetic ingredients are not required to show long-term safety and endocrine effects with chronic skin exposure.

Skincare marked as “Clean Beauty” usually does not contain any endocrine disruptors or hormones, but the definition of clean beauty is not standardized. Which skincare ingredients are considered endocrine disrupters and are found on lists of toxic skincare ingredients by organizations such as the EWG.

• Parabens (methylparaben, ethylparaben, propylparaben, butylparaben)
• Benzophenones (oxybenzone, sulisobenzone)
• Phthalates (dimethyl phthalate, diethyl phthalate, dibutyl phthalate)
• Triclosan
• Octinoxate
• Homosalate
• Octocrylene
• Paraffin/mineral oil
• BHA & BHT preservatives
• Formaldehyde
• Fragrance/parfum
• Retinyl palmitate
• Soy extracts (glycine soja)
• Genistein
• Daidzein
• Resorcinol
• Hydroquinone

• Certain dyes & colorants

The best way to find estrogen free and hormone free skincare is to read the product labels.  Here are some clean products that are free of endocrine disruptors:

If you are looking for estrogen free skincare, estrogen free makeup, and beauty products without endocrine disruptors these are the ingredients to look for on product labels to avoid.

• Blue 1 Lake (Ci 42090)

• D & C Red 33 (Ci 17200)

• Ext Violet 2 (Ci 60730)

• Yellow 6 (Ci 15985)

• Methylparaben
• Ethylparaben
• Propylparaben
• Butylparaben
• BHA- butylated hydroxyanisole
• BHT- butylated hydroxytoluene

• Avobenzone
• Benzophenones (i.e. oxybenzone)
• Octinoxate-
• Homosalate
• Octocrylene

• Musk tibetene

Soy, genistein, resveratrol and methyl estradiolpropanoate  are considered safe estrogen agonists in skincare and are used in skincare products to treat menopausal skin.  Men and sensitive groups may choose to avoid using these over larger body areas for long periods of time . However, they have many benefits that seem to outweigh any risks.

Methyl Estradiolpropanoate (MEP) is a synthetic estrogenic sterol ester used in skin care products as a non-hormonal way to activate the estrogen receptor. It is called a Non-hormonal Estrogen Receptor Activator (NERA). MEP is used topically to treat estrogen deficient skin (EDS) and enhance the appearance of postmenopausal women's faces. Clinical studies show MEP is safe, effective and without hormonal side effects.

Though it mimics estrogen superficially in skin, MEP gets metabolized into an inactive compound - avoiding systemic estrogenic impacts. Once absorbed into the bloodstream, MEP quickly converts to an inactive metabolite. So despite local estrogen-like skin activity, no internal hormone disruption or reproductive consequences occur.

Restoring estrogen responses locally allows MEP to improve facial skin quality without endocrine activation or safety concerns in either sex. The poor absorption but visible benefits underscore how topical estrogens can bypass broader hormonal changes if doses remain low and skin-centric. Follow-up research will further illuminate if these cosmeceutical exposures modify intrinsic skin aging without risks linked to circulating estrogens long-term.

MEP is the active ingredient in the Emepelle line of topical skin care products aiming to reverse estrogen deficiency manifestations in aging skin after menopause. But its precise, localized mechanism of action differs greatly from traditional systemic hormone therapy.

Not all soy extracts (glycine soja) have estrogenic effects. The type of soy to avoid is unfermented soy.

Soy phospholipids (like soy lecithin) - Appear to have MINIMAL estrogenic activity and low potential endocrine impact. Soy lecithin contains very low amounts of bioactive isoflavones that drive hormonal effects. These are safe for men and sensitive groups to use in skincare.

Soybean proteins-

Two proteins in soy called they STI (soybean trypsin inhibitor) and BBI (Bowman-Birk protease inhibitor) are PAR-s blockers and used to reduce skin pigmentation.  The proteins have been extracted from soy and do not have any estrogenic activity. (They are most often found in Aveeno skincare products.)

Unfermented soy extracts - 

• These contain higher levels of isoflavone compounds like genistein and daidzein which show estrogenic properties. Unfermented soy has the most estrogenic effects. 

  
  

  Examples of Unfermented Soy:

• Soy milk
• Tofu
• Soy protein isolates (used in processed foods and protein powders)
• Edamame
• Soy nuts
• Soybeans

• Soy flour most concern for endocrine disruption. 

  
  

  Fermented soy extracts - The fermentation process converts potent isoflavones like genistein and other derivatives. So fermented soy has little or  no estrogenic activity.

  
  

   Examples of Fermented Soy:

• Tempeh - made from fermented soybeans
• Miso - soybean paste, fermented with grains
• Soy sauce - made from fermented soybeans and wheat
• Natto - sticky soybeans fermented by bacterial cultures
• Fermented tofu

• Fermented soy beverages like kombucha

  
  

In summary:

Soy lecithin, soy  phospholipids and soy proteins STI and BBI ingredients have the lowest potential endocrine impact:.

 Unfermented soybean extracts like soy milk, edamame and tofu  have a higher potential estrogenic effect.

Resveratrol is considered a phytoestrogen. Laboratory studies expose cells to very high resveratrol doses that don't reflect real-world diet or skincare. But they show mechanisms that resveratrol may be able to:

1. Directly activate estrogen receptors similar to natural estrogens
2. Boost estrogen production
3. Slow estrogen breakdown

So in theory resveratrol  use could subtly shift overall hormone balance. But this is likely very dependent on dose and whether you are using a topical serum or cream or an oral form. Small amounts absorbed through the skin may have little effect while grams taken orally daily have more of an effect. We lack data defining exactly how much resveratrol penetrates skin when used topically to raise any red flags around using common cosmetic concentrations. Plus skin creams don't enter the liver where metabolic conversion ramps up resveratrol's potency. So topical use of resveratrol seems low risk.

In contrast, consistently mega-dosing resveratrol supplements long-term may present more realistic concern over gradually accruing estrogenic side effects. Though more human data is still needed. In moderation, resveratrol likely poses little threat to endocrine health. But if you are in one of the sensitive groups, you may choose to avoid resveratrol.

Genistein, an isoflavone compound found abundantly in soybeans, behaves as a phytoestrogen that preferentially binds and activates ERβ over ERα. In females, it can suppress ovarian function and steroidogenesis when administered at high doses, while also demonstrating therapeutic potential for conditions like PCOS. Outcomes in pregnancy appear complex, with both positive and negative impacts depending on dose, timing, species differences and more. Genistein also interacts with male reproductive pathways, exacerbating testicular damage together with endocrine disruptors like phthalates. While displaying some beneficial influence on sperm at low doses short-term, prolonged exposures correlated with declining sperm quality and fertility in animal studies. Beyond direct hormone-related effects, developmental genistein exposure can also reprogram epigenetic markers in reproductive tissues of both sexes. Elucidating the biological potency of genistein requires substantial further research to translate findings in animal models to humans and establish definitive safety thresholds for exposures from dietary intake. But current evidence indicates impacts on reproductive health for adults and developing offspring deserve consideration given the prevalence of soybean-derived food products

Phytoestrogens are essentially non-steroidal, plant-derived chemicals that can elicit estrogen-like activity in the body.

These are examples of phytoestrogens:

• Genistein and daidzein - derived from soybeans
• Glycitein - found in soybean/soy products along with genistein and daidzein
• Coumestrol - a compound found in clover and some legumes
• Formononetin - found in red clover (Trifolium pratense)
• Biochanin A - red clover is also a common plant source
• Quercetin - a flavonoid found in a variety of fruits, vegetables, leaves, grains
• Resveratrol - found in grape skins, berries, peanuts
• Musestrol and cycloartanol - derived from musk rose oil

• Matairesinol and secoisolariciresinol - found in flax seed lignan

  
  

The major food-based sources of compounds classified as phytoestrogens are soy, legumes like clover, flax seed, and a wide variety of fruits/veggies.  The compounds listed above are some examples found in common dietary phytoestrogen sources.

Right now many safe cosmetic use limits are based on shorter term exposures on small areas of the body. But longer testing periods or using the ingredient all over the body may reveal impacts not captured in  small short term exposures. Ingredient safety requires continuous reassessment as new science links exposures to biological changes over time. There is a lot of misinformation and fear, so I will try and keep you up to date on the science and what we really know vs what we think we know. Stay up to date on cosmetic ingredient safety by following us on social media.

And don't forget to take the skin type quiz to know your Baumann Skin Type.  This helps you know which ingredients that YOU should avoid.

[[ctaquiz]]

1. Baumann L. Antiaging Ingredients in Ch. 37 of Baumann's Cosmetic Dermatology Ed 3. (McGraw Hill 2022)
2. Baumann, L. Cosmeceuticals and Cosmetic Ingredients (McGraw Hill 2015)
3. Qasem, R. J. (2020). The estrogenic activity of resveratrol: A comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Critical Reviews in Toxicology, 50(5), 439-462.
4. Gehm, B. D., McAndrews, J. M., Chien, P. Y., & Jameson, J. L. (1997). Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proceedings of the National Academy of Sciences, 94(25), 14138-14143.
5. Mascarenhas-Melo, F., Araújo, A. R., Rodrigues, M., Mathur, A., Gonçalves, M. B. S., Tanwar, K., ... & Paiva-Santos, A. C. (2023). Dermatological Bioactivities of Resveratrol and Nanotechnology Strategies to Boost Its Efficacy—An Updated Review. Cosmetics, 10(3), 68.
6. Kluska, M., Jabłońska, J., & Prukała, W. (2023). Analytics, Properties and Applications of Biologically Active Stilbene Derivatives. Molecules, 28(11), 4482.
7. Wang, T. T., Sathyamoorthy, N., & Phang, J. M. (1996). Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis, 17(2), 271-275.
8. Hsieh, C. Y., Santell, R. C., Haslam, S. Z., & Helferich, W. G. (1998). Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer research, 58(17), 3833-3838.
9. Guelfi, G., Pasquariello, R., Anipchenko, P., Capaccia, C., Pennarossa, G., Brevini, T. A., ... & Maranesi, M. (2023). The Role of Genistein in Mammalian Reproduction. Molecules, 28(21), 7436.
10. Daniel, S., Reto, M., & Fred, Z. (2001). Dermatological application of soy isoflavones to prevent skin ageing in postmenopausal women. Cosmet. Toiletries Manuf. Worldw, 1, 146-151.
11. Shidhaye, S., Malke, S., Mandal, S., Sakhare, N., & Kadam, V. (2008). Soy-A Hidden Treasure for Therapeutic, Cosmetic and Pharmaceutical Use. The Internet Journal of Alternative Medicine, 7(2).
12. Liu, J. C., Wu, J., & Seiberg, M. (2017). Applications of Non-Denatured Soy in Skin Care. Textbook of Cosmetic Dermatology, 105-124.
13. Cohen, J. L. (2019). Evaluation of efficacy of a skin care regimen containing methyl estradiolpropanoate (MEP) for treating estrogen deficient skin. Journal of drugs in dermatology: JDD, 18(12), 1226-1230.
14. Cohen, J., & Downie, J. (2022). An Open-Label Study Evaluating the Periorbital Skin Rejuvenation Efficacy of a Cosmeceutical Containing Methyl Estradiolpropanoate (MEP) in Women With Estrogen Deficient Skin (EDS). Journal of Drugs in Dermatology: JDD, 21(11), 1185-1190.
15. Draelos, Z. D. (2018). A double-blind randomized pilot study evaluating the safety and efficacy of topical MEP in the facial appearance improvement of estrogen deficient females. Journal of Drugs in Dermatology: JDD, 17(11), 1186-1189.